Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

Cited by (901)

Items 101–200 of 901

1. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
   Arrigo F.G. Cicero, Federica Fogacci, Adrián Vladimir Hernández, Maciej Banach · 2020 · PLoS Medicine
2. Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk
   Mark Trinder, Kaavya Paruchuri, Sara Haidermota, Rachel C. Bernardo, Seyedeh Maryam Zekavat, Thomas Gilliland, James L. Januzzi, Pradeep Natarajan · 2022 · Journal of the American College of Cardiology
3. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
   Khunti, Kamlesh, Kosiborod, Mikhail, Ray, Kausik K. · 2018 · Diabetes, Obesity and Metabolism
4. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy
   Rishi Puri, Steven E. Nissen, Mingyuan Shao, Christie Mitchell Ballantyne, Philip J. Barter, M. John Chapman, Raimund M. Erbel, Peter Libby, J.S. Raichlen, K. Uno et al. · 2013 · European Heart Journal
5. Abstract
   Burgess, S · 2018 · Apollo (University of Cambridge)
6. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease
   Ting Sun, Mengyun Chen, Huanhuan Shen, PingYin, Fan Li, Xin Chen, Jun Wu, Zuojun Xu, Junfeng Zhang · 2022 · BMC Cardiovascular Disorders
7. How to use Mendelian randomization to anticipate the results of randomized trials
   Ference, Brian A · 2018 · European Heart Journal
8. PCSK9: From discovery to therapeutic applications
   Michel Farnier · 2014 · Archives of cardiovascular diseases
9. Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation
   Daniel J. Conklin, Suzaynn F. Schick, Michael Joseph Blaha, Alex P. Carll, Andrew Paul DeFilippis, Peter Ganz, Michael E. Hall, Naomi M. Hamburg, Timothy E. O’Toole, Lindsay M. Reynolds et al. · 2019 · American Journal of Physiology-Heart and Circulatory Physiology
10. HDL and cardiovascular disease
    Stephen James Nicholls, Adam J. Nelson · 2019 · Pathology
11. Association between major depressive disorder and multiple disease outcomes: a phenome-wide Mendelian randomisation study in the UK Biobank
    Anwar Mulugeta, Ang Zhou, Catherine E. King, Elina Hyppönen · 2019 · Molecular Psychiatry
12. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
    Parish, Sarah, Hopewell, Jemma C., Hill, Michael R., Marcovina, Santica, Valdes-Marquez, Elsa, Haynes, Richard, Offer, Alison, Pedersen, Terje R., Baigent, Colin, Collins, Rory et al. · 2018 · Circulation: Genomic and Precision Medicine
13. Statins: Then and Now
    Peter Paul Toth, Maciej Banach · 2019 · Methodist DeBakey Cardiovascular Journal
14. Evidence-based goals in LDL-C reduction
    Soran, Handrean, Dent, Ricardo, Durrington, Paul · 2017 · Clinical Research in Cardiology
15. Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol
    Marios K. Georgakis, Rainer Malik, Christopher D. Anderson, Klaus Georg Parhofer, Jemma C. Hopewell, Martin Dichgans · 2019 · Brain
16. Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review.
    R. Nielsen, V. Fuster, H. Bundgaard, J. J. Fuster, A. Johri, K. F. Kofoed, Pamela S. Douglas, A. Diederichsen, Michael D. Shapiro, S. J. Nicholls et al. · 2024 · Journal of the American College of Cardiology
17. Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors
    Stephen Burgess, Adam S. Butterworth, John Russell Thompson · 2015 · Journal of Clinical Epidemiology
18. Management of residual risk after statin therapy
    Christina A. Reith, Jane Armitage · 2015 · Atherosclerosis
19. Curing atherosclerosis should be the next major cardiovascular prevention goal
    Robinson, Jennifer G., Gidding, Samuel S. · 2014 · Journal of the American College of Cardiology
20. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease
    George Thanassoulis, Ken Williams, Kathleen K. Altobelli, Michael J. Pencina, Christopher Paul Cannon, Allan D. Sniderman · 2016 · Circulation
21. The Treatment of Disorders of Lipid Metabolism
    Klaus Georg Parhofer · 2016 · Deutsches Ärzteblatt international
22. Mechanisms of acute coronary syndromes.
    Diego Gómez-Arbeláez, Patricio A López-Jaramillo · 2013 · PubMed
23. Extending Causality Tests with Genetic Instruments: An Integration of Mendelian Randomization with the Classical Twin Design
    Minică, Camelia C., Dolan, Conor V., Boomsma, Dorret I., de Geus, Eco, Neale, Michael C. · 2018 · Behavior Genetics
24. Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies
    Lin Xu, Zezhong Tian, Hong Chen, Yimin Zhao, Yan Yang · 2021 · Frontiers in Nutrition
25. Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration
    Raymond Noordam, Maxime M. Bos, Heming Wang, Thomas W. Winkler, Amy R. Bentley, Tuomas O. Kilpeläinen, Paul S. de Vries, Yun Ju Sung, Karen Schwander, Brian E. Cade et al. · 2019 · Nature Communications
26. Plant Based Diet and Its Effect on Cardiovascular Disease
    Salman Salehin, Peter Rasmussen, steven mai, Muhammad Mushtaq, Mayank Agarwal, Syed Mustajab Hasan, Shahran Salehin, Muhammad Waheed Raja, Syed Amir Gilani, Wissam I. Khalife · 2023 · International Journal of Environmental Research and Public Health
27. Mendelian randomization studies
    Brian A. Ference · 2015 · Current Opinion in Lipidology
28. Progress and perspectives in plant sterol and plant stanol research
    Peter J.H. Jones, Maryam Shamloo, Dylan MacKay, Todd Christopher Rideout, Semone B. Myrie, Jogchum Plat, Jean‐Baptiste Roullet, David J. Baer, Kara L. Calkins, Harry R. Davis et al. · 2018 · Nutrition Reviews
29. How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
    Kimberly N. Hong, Valentı́n Fuster, Robert S. Rosenson, Clive Rosendorff, Deepak L. Bhatt · 2017 · Journal of the American College of Cardiology
30. Mendelian randomization accounting for complex correlated horizontal pleiotropy while elucidating shared genetic etiology
    Qing Cheng, Xiao Zhang, Lin Chen, Jin Liu · 2022 · Nature Communications
31. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease
    Bo Kobberø Lauridsen, Stefan Stender, Ruth Frikke‐Schmidt, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen · 2015 · European Heart Journal
32. Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes
    Luca Andrea Lotta, Isobel D. Stewart, Stephen J. Sharp, Felix R. Day, Stephen Burgess, Jian’an Luan, Nicholas Bowker, Lina Cai, Chen Li, Laura B. L. Wittemans et al. · 2018 · JAMA Cardiology
33. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals
    James A. Underberg, Peter Paul Toth, Fátima Rodríguez · 2022 · Postgraduate Medicine
34. Effects of 20-year infancy-onset dietary counselling on cardiometabolic risk factors in the Special Turku Coronary Risk Factor Intervention Project (STRIP): 6-year post-intervention follow-up
    Katja Pahkala, Tomi T. Laitinen, Harri Niinikoski, Noora Kartiosuo, Suvi Rovio, Hanna Lagström, Britt-Marie Loo, Pia Salo, Eero V. Jokinen, Costan G. Magnussen et al. · 2020 · The Lancet Child & Adolescent Health
35. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
    Preiss, David, Tobert, Jonathan A., Hovingh, G. Kees, Reith, Christina · 2020 · Journal of the American College of Cardiology
36. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
    Jemma C. Hopewell, Rainer Malik, Elsa Valdés‐Márquez, Bradford B. Worrall, Rory Collins · 2017 · European Heart Journal
37. Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care
    Uma Ramaswami, Steve Eric Humphries, Lorraine Priestley-Barnham, Peter Green, David S Wald, Nigel E. Capps, Mark Anderson, Peter Dale, A. A. M. Morris · 2019 · Atherosclerosis
38. The Role of Endothelial Cells in Atherosclerosis
    Mark E. Pepin, Rajat M. Gupta · 2023 · American Journal Of Pathology
39. Mining the Human Phenome Using Allelic Scores That Index Biological Intermediates
    David M. Evans, Marie‐Jo Brion, Lavinia Paternoster, John P. Kemp, George McMahon, Marcus Robert Munafo, John B. Whitfield, Sarah Elizabeth Medland, Grant W. Montgomery, Nicholas John Timpson et al. · 2013 · PLoS Genetics
40. Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
    Baihui Zhang, Fan Yin, Ya-Nan Qiao, Shoudong Guo · 2022 · Frontiers in Molecular Biosciences
41. HOPS: a quantitative score reveals pervasive horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of human traits and diseases
    Jordan, Daniel M., Verbanck, Marie, Do, Ron · 2019 · Genome Biology
42. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—The zero-LDL hypothesis
    L. Masana, Josefa Girona, Daiana Ibarretxe, Ricardo Rodríguez‐Calvo, Roser Rosales, Joan-Carles Vallvé, Cèlia Rodríguez-Borjabad, Montse Guardiola, M. Mar Rodríguez, Sandra Guaita‐Esteruelas et al. · 2018 · Journal of clinical lipidology
43. Relative effects of LDL-C on ischemic stroke and coronary disease
    Elsa Valdés‐Márquez, Sarah Parish, Robert Clarke, Traiani Stari, Bradford B. Worrall, Jemma C. Hopewell · 2019 · Neurology
44. Mendelian Randomization Analysis Identifies CpG Sites as Putative Mediators for Genetic Influences on Cardiovascular Disease Risk
    Tom G. Richardson, Jie Zheng, George Davey Smith, Nicholas John Timpson, Tom R. Gaunt, Caroline L. Relton, Gibran Hemani · 2017 · The American Journal of Human Genetics
45. Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
    Wang, Nelson, Woodward, Mark, Huffman, Mark D., Rodgers, Anthony · 2022 · Circulation: Cardiovascular Quality and Outcomes
46. Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk
    Sumeet A. Khetarpal, Daniel James Rader · 2015 · Arteriosclerosis Thrombosis and Vascular Biology
47. Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
    Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos · 2023 · Journal of the American Heart Association
48. Investigating the shared genetics of non-syndromic cleft lip/palate and facial morphology
    Laurence J Howe, Myoung Keun Lee, Gemma C. Sharp, George Davey Smith, Beaté St Pourcain, John R. Shaffer, Kerstin U. Ludwig, Elisabeth Mangold, Mary L. Marazita, Eleanor Feingold et al. · 2018 · PLoS Genetics
49. Transcription Factor MAFF (MAF Basic Leucine Zipper Transcription Factor F) Regulates an Atherosclerosis Relevant Network Connecting Inflammation and Cholesterol Metabolism
    Moritz von Scheidt, Yuqi Zhao, Thomas Q. de Aguiar Vallim, Nam Che, Michael Wierer, Marcus Michael Seldin, Oscar Franzén, Zeyneb Kurt, Shichao Pang, Dario Bongiovanni et al. · 2021 · Circulation
50. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV
    Raman Puri, Manish Bansal, Vimal Mehta, Paul Barton Duell, Nathan D. Wong, SS Iyengar, Dinesh Kumar Kalra, Devaki R. Nair, Navin C. Nanda, Jagat Narula et al. · 2024 · Journal of clinical lipidology
51. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
    Allan D. Sniderman, Shofiqul Islam, Matthew McQueen, Michael J. Pencina, Curt Daniel Furberg, George Thanassoulis, Salim Yusuf · 2016 · Journal of the American Heart Association
52. Effects of endurance training on serum lipids
    Fikenzer, Kati, Fikenzer, Sven, Laufs, Ulrich, Werner, Christian · 2018 · Vascular Pharmacology
53. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia
    Sofía Pérez‐Calahorra, Martín Laclaustra, Victoria Marco-Benedí, Itziar Lamíquiz-Moneo, Juan Pedro‐Botet, Núria Plana, Rosa M. Sánchez-Hernández, Antonio Jesús Amor, Fátima Almagro, Francisco J. Fuentes et al. · 2019 · Atherosclerosis
54. Polygenic Hypercholesterolemia and Cardiovascular Disease Risk
    Mahtab Sharifi, Marta Futema, Devaki R. Nair, Steve Eric Humphries · 2019 · Current Cardiology Reports
55. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose‐lowering interventions
    Ronan Roussel, Philippe Gabríel Steg, Kamel Mohammedi, Michel Marre, Louis Potier · 2017 · Diabetes Obesity and Metabolism
56. Recomendaciones para mejorar el control lipídico. Documento de consenso de la Sociedad Española de Cardiología
    Carlos Escobar, Manuel P. Anguita, Vicente Arrarte, Vivencio Barrios, Angel R. Cequier, Juan Cosı́n-Sales, Isabel Egocheaga, Esteban López de Sá, L. Masana, Vicente Pallarés‐Carratalá et al. · 2019 · Revista Española de Cardiología
57. RETRACTED ARTICLE: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
    Amir Abbas Momtazi‐Borojeni, Mahmoud Reza Jaafari, Ali Badiee, Maciej Banach, Amirhossein Sahebkar · 2019 · BMC Medicine · Retracted
58. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Zanfina Ademi, Richard Norman, Jing Pang, Danny Liew, Sophia Zoungas, Eric J.G. Sijbrands, Brian A. Ference, Albert Wiegman, Gerald Francis Watts · 2020 · Atherosclerosis
59. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
    Paul M. Ridker, Pierre Amarenco, Robert Brunell, Robert J. Glynn, J. Wouter Jukema, John J.P. Kastelein, Wolfgang Köenig, Steven E. Nissen, James H. Revkin, Raul Dias Santos et al. · 2016 · American Heart Journal
60. Molecular Biomarkers for Cardiometabolic Disease: Risk Assessment in Young Individuals
    Usman A. Tahir, Robert Edgardo Gerszten · 2023 · Circulation Research
61. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries
    Toshiyuki Nishikido, Kausik Kumar Ray · 2019 · Frontiers in Cardiovascular Medicine
62. Body mass index and colorectal cancer risk: A Mendelian randomization study
    Shiori Suzuki, Atsushi Goto, Masahiro Nakatochi, Akira Narita, Taiki Yamaji, Norie Sawada, Ryoko Katagiri, Masao Iwagami, Akiko Hanyuda, Tsuyoshi Hachiya et al. · 2021 · Cancer Science
63. Hyperlipidemia and Cardiovascular Risk in Children and Adolescents
    Francesca Mainieri, Saverio La Bella, Francesco Chiarelli · 2023 · Biomedicines
64. Screening for Lipid Disorders in Children and Adolescents
    Janelle Guirguis‐Blake, Corinne V. Evans, Erin L. Coppola, Nadia Redmond, Leslie A Perdue · 2023 · JAMA
65. Association of Maternal Prepregnancy Dyslipidemia With Adult Offspring Dyslipidemia in Excess of Anthropometric, Lifestyle, and Genetic Factors in the Framingham Heart Study
    Mendelson, Michael M., Lyass, Asya, O’Donnell, Christopher J., D’Agostino, Ralph B., Levy, Daniel · 2016 · JAMA Cardiology
66. Insight into rheumatological cause and effect through the use of Mendelian randomization
    Philip Cameron Robinson, Hyon K. Choi, Ron Do, Tony Raymond Merriman · 2016 · Nature Reviews Rheumatology
67. Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction
    Giulia Chiesa, Marco Busnelli, Stefano Manzini, Cinzia Parolini · 2016 · Marine Drugs
68. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease
    Stephen Burgess, Eric L. Harshfield · 2016 · Current Opinion in Endocrinology Diabetes and Obesity
69. Cholesterol Transport Revisited: A New Turbo Mechanism to Drive Cholesterol Excretion
    Jan Freark de Boer, Folkert Kuipers, Albert Kornelis Groen · 2017 · Trends in Endocrinology and Metabolism
70. Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users
    Sung, Huh, Seungho Ryu, Lee, Eleonora Scorletti, Christopher D. Byrne, Jang Young Kim, Dae-Sung Hyun, Sang-Baek Ko · 2019 · Journal of Clinical Medicine
71. Mendelian randomization while jointly modeling cis genetics identifies causal relationships between gene expression and lipids
    Adriaan van der Graaf, Annique Claringbould, Antoine Rimbert, Bastiaan T. Heijmans, Peter A.C. ’t Hoen, Joyce B. J. van Meurs, Rick Jansen, Lude Franke, Harm-Jan Westra, Yang Li et al. · 2020 · Nature Communications
72. The association between blood PFAS concentrations and clinical biochemical measures of organ function and metabolism in participants of the Canadian Health Measures Survey (CHMS)
    Sabit Cakmak, Anna O. Lukina, Subramanian Karthikeyan, Ella Atlas, Robert Dales · 2022 · The Science of The Total Environment
73. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)
    Rishi Puri, Steven E. Nissen, Ransi M. Somaratne, Leslie Cho, John J.P. Kastelein, Christie Mitchell Ballantyne, Wolfgang Köenig, Todd J. Anderson, Jingyuan Yang, Helina Kassahun et al. · 2016 · American Heart Journal
74. The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
    Jing Pang, Dick C. Chan, Gerald Francis Watts · 2020 · Current Atherosclerosis Reports
75. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table
    Mach, François, Visseren, Frank L.J., Cater, Nilo B., Salhi, Nejoua, Soronen, Jarkko, Ray, Kausik K., Delgado, Victoria, Jukema, J. Wouter, Laufs, Ulrich, Zamorano, Jose-Luis et al. · 2024 · Journal of Clinical Lipidology
76. Cholesterol confusion and statin controversy
    Robert J. DuBroff · 2015 · World Journal of Cardiology
77. Plant sterol enriched functional food and atherosclerosis
    Jürgen Köhler, Daniel Teupser, Albrecht Elsässer, Oliver Weingärtner · 2017 · British Journal of Pharmacology
78. Association Between Family History, a Genetic Risk Score, and Severity of Coronary Artery Disease in Patients With Premature Acute Coronary Syndromes
    Waseem Hindieh, Louise Pilote, Asim Nazir Cheema, Hatim Al-Lawati, Christopher Labos, Line Dufresne, James C. Engert, George Thanassoulis · 2016 · Arteriosclerosis Thrombosis and Vascular Biology
79. Bempedoic Acid (ETC-1002)
    Saeed, Anum, Ballantyne, Christie M. · 2018 · Cardiology Clinics
80. Advances in treatment of Dyslipidemia
    Dybiec, Jill, Baran, Wiktoria, Dąbek, Bartłomiej, Fularski, Piotr, Młynarska, Ewelina, Radzioch, Ewa, Rysz, Jacek, Franczyk, Beata · 2023 · International Journal of Molecular Sciences
81. Screening for Lipid Disorders in Children and Adolescents
    US Preventive Services Task Force, Michael J. Barry, Wanda Kay Nicholson, Michael Silverstein, David P. Chelmow, Tumaini R. Coker, Esa M. Davis, Katrina E Donahue, Carlos Roberto Jaén, Li Li et al. · 2023 · JAMA
82. Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services
    Alistair W. Vickery, Damon A. Bell, Jacquie Garton‐Smith, Andrew B. Kirke, Jing Pang, Gerald Francis Watts · 2014 · Heart Lung and Circulation
83. Assessment of the Role of Carotid Atherosclerosis in the Association Between Major Cardiovascular Risk Factors and Ischemic Stroke Subtypes
    Sarah Parish, Matthew Arnold, Robert Clarke, Huaidong Du, Eric Yuk Fai Wan, Om Kurmi, Yiping Chen, Canqing Yu, Zheng Bian, Rory Collins et al. · 2019 · JAMA Network Open
84. Co-expression analysis reveals interpretable gene modules controlled by trans-acting genetic variants
    Liis Kolberg, Nurlan Kerimov, Hedi Peterson, Kaur Alasoo · 2020 · eLife
85. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
    Maya S. Safarova, Tia Bimal, Daniel E. Soffer, Benjamin J. Hirsh, Michael David Shapiro, Guy L. Mintz, Agnes Cha, Eugenia Gianos · 2024 · American Journal of Preventive Cardiology
86. Does Dietary Cholesterol Matter?
    Scott M. Grundy · 2016 · Current Atherosclerosis Reports
87. The Global Burden of Diseases attributed to high low-density lipoprotein cholesterol from 1990 to 2019
    Jia Zheng, Jing Wang, Yan Zhang, Jiangliu Xia, Huilan Guo, Haiying Hu, Peng‐Fei Shan, Tianlang Li · 2022 · Frontiers in Public Health
88. Cholesterol-Lowering Agents
    Savvas Hadjiphilippou, Kausik Kumar Ray · 2019 · Circulation Research
89. Accuracy of low-density lipoprotein cholesterol estimation at very low levels
    Renato Quispe, Aditya D. Hendrani, Mohamed Badreldin Elshazly, Erin D. Michos, John William McEvoy, Michael Joseph Blaha, Maciej Banach, Krishnaji R. Kulkarni, Peter Paul Toth, Josef Coresh et al. · 2017 · BMC Medicine
90. Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
    Jack Stewart, Katherine Addy, Sarah Campbell, Peter Wilkinson · 2020 · JRSM Cardiovascular Disease
91. Knowns and unknowns in the care of pediatric familial hypercholesterolemia
    Andrew C. Martin, Samuel S. Gidding, Albert Wiegman, Gerald Francis Watts · 2017 · Journal of Lipid Research
92. Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes
    Janne Pott, Valentin Schlegel, Andrej Teren, Katrin Horn, Holger Kirsten, Christina Blücher, Jüergen Kratzsch, Markus Loeffler, Joachim Thiery, Ralph Burkhardt et al. · 2018 · Circulation Genomic and Precision Medicine
93. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options
    Adam N. Berman, Ron Blankstein · 2019 · Current Cardiology Reports
94. How Do Statins Work?
    Michael Joseph Blaha, Seth Shay Martin · 2013 · Journal of the American College of Cardiology
95. Dyslipidemia in pediatrician’s practice
    Alla V. Burlutskaya, Victoria E. Tril, Lily V. Polischuk, Vladimir M. Pokrovskii · 2021 · Reviews in Cardiovascular Medicine
96. Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review
    Arrigo F.G. Cicero, Federica Fogacci, Anca Pantea Stoian, Peter Paul Toth · 2023 · Nutrients
97. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
    Scott B. Vafai, Jörg Täubel, Thomas Ashdown, Riyaz S. Patel, Sadaf Diamondali, Jaimini Cegla, Handrean Soran, Bilal Bashir, Alexander Abitbol, Daniel Gaudet et al. · 2026 · New England Journal of Medicine
98. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
    L. M. Strilchuk, Federica Fogacci, Arrigo F.G. Cicero · 2019 · Expert Opinion on Drug Safety
99. Machine learning applications for therapeutic tasks with genomics data
    Kexin Huang, Cao Xiao, Lucas M. Glass, Cathy W. Critchlow, Greg C. Gibson, Jimeng Sun · 2021 · Patterns
100. Risk and the Physics of Clinical Prediction
     John William McEvoy, George A. Diamond, Robert Detrano, Sanjay Kaul, Michael Joseph Blaha, Roger Scott Blumenthal, Steven Richard Jones · 2014 · The American Journal of Cardiology